Target

PIK3CD

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform

As of the edition of 20 October 2026, PIK3CD (phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, UniProt O00329) has 49 drugs tested at it and 48 companies on the list, 27 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
O00329
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Solved structures
20
Disease areas
Cancer; Blood and lymph; Immune system; Skin and connective tissue; Lungs and airways; Urinary and reproductive; Nervous system; Pregnancy and women's health
Registered trials of its drugs
626

Drugs at this target

StatusCount
Marketed5
Active7
Went quiet15
Stopped17
Withdrawn from market1
Status not established4
Total49
DrugStatusFurthest phaseUS protection
BuparlisibStoppedPhase 3none listed
CopanlisibMarketedPhase 3Ends 2032
IdelalisibMarketedPhase 4Ends 2033
DuvelisibMarketedPhase 3Ends 2032
ParsaclisibActivePhase 3none listed
UmbralisibWithdrawn from marketPhase 3Ends 2035
DactolisibWent quietPhase 3none listed
LinperlisibActivePhase 4none listed
GedatolisibMarketedPhase 3Ends 2031
SamotolisibStoppedPhase 2none listed
PictilisibWent quietPhase 2none listed
TaselisibStoppedPhase 3none listed

12 of 49 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A27
Route B5
Engaged12
Undetermined4
Total on the list48
Three companies on route A or B, with the route only
CompanyRoute
Gilead SciencesRoute B
GSKRoute A
AmgenRoute A

The other 45 companies at PIK3CD

In the product

48 companies in all; 45 are not named here, and no score is.

See the 48 companies at PIK3CD, ranked, with the facts behind eachRequest access. Nothing is shown until you do.